Light Therapy for Brain Health: What the Science Shows

The Research

Red light therapy has become increasingly recognized as a beneficial wellness approach, with scientists investigating its possible medical uses. Transcranial photobiomodulation (tPBM) is a novel treatment that employs low-level red or near-infrared (NIR) light to affect brain activity, with the goal of aiding those suffering from depression, mild cognitive impairment, and various neurological disorders.

This technique involves the application of specific light wavelengths (usually between 800–1064 nm) through the scalp to activate mitochondria, the cellular powerhouses in brain neurons. The absorption of these wavelengths appears to enhance cellular energy production and improve mitochondrial function, potentially leading to increased ATP generation, enhanced cerebral blood circulation, elevated levels of brain-derived neurotrophic factor (BDNF), and decreased oxidative stress and inflammation.

These transformations may bolster the resilience of brain cells and promote synaptic plasticity, which is the brain's capacity to create, strengthen, and reorganize neural connections. Current studies suggest that tPBM may exert its most significant effects on superficial cortical areas, particularly the prefrontal cortex. Clinical enhancements are most reliably observed in executive functioning, attention, and working memory—functions predominantly managed by the prefrontal cortex. Nonetheless, the extent of light penetration and the consistency of clinical effects in specific domains remain subjects of ongoing research.

The limited ability of light to reach the hippocampus, situated deeper in the brain, may clarify why substantial memory improvements are less frequently reported in clinical trials. This has prompted active exploration of tPBM as a promising method for boosting cognitive function, decelerating neurodegenerative conditions like dementia, and addressing mental health disorders.

The Possible Advantages

The following conditions have the most substantial evidence supporting them:

• Depression: tPBM has demonstrated potential in alleviating depressive symptoms, with recent meta-analyses showing an overall moderate effect size across various studies. Notably, some trials comparing whole-body red light therapy to transcranial light therapy indicate a stronger effect with whole-body therapy, although transcranial therapy may still offer benefits. The reasons for this discrepancy remain unclear, but researchers hypothesize it may be linked to broader systemic impacts on mitochondrial function, inflammation, and blood flow.

  
  

• Cognitive Impairment: tPBM has shown promising cognitive enhancements in individuals experiencing age-related cognitive decline, including subjective cognitive complaints, mild cognitive impairment (MCI), and dementia, though the evidence is still limited and effects vary among these populations. Research and meta-analyses indicate improvements in overall cognition, working memory, and certain executive-function measures, with some studies reporting memory benefits, although not consistently. Most findings stem from transcranial rather than whole-body light therapy. Some studies have noted lasting benefits for months, but the durability of these effects remains an area for further investigation.

  
  

• Traumatic Brain Injuries (TBI): In cases of TBI, tPBM has shown promising results regarding cognitive efficiency, working memory, learning, sleep quality, pain management, and symptoms related to post-concussion and PTSD in certain studies, including a recent randomized placebo-controlled trial that revealed both statistically and clinically significant improvements. However, the evidence is mixed, and not all randomized trials have demonstrated benefits.

  
  

• Cognitive Performance in Healthy Adults: Transcranial light therapy has been associated with modest yet significant enhancements in working memory, attention, and some studies have noted improved word retrieval. Effects on overall cognition are less pronounced, and memory benefits tend to be limited, likely due to the shallow penetration of light and a ceiling effect in high-functioning individuals.

  
  

These conditions have less evidence and necessitate further research:

• Anxiety: The effects on anxiety are inconsistent and less explored than in depression, with some encouraging findings but not enough evidence to draw definitive conclusions.

  
  

• Stroke, Parkinson’s Disease, and Epilepsy: For these conditions, preclinical and early clinical investigations suggest potential benefits in neuroprotection, neural repair, cerebral blood flow, and functional outcomes; however, the evidence remains preliminary and large-scale trials are still needed.

  
  

• Other Mental Health Conditions, including bipolar disorder: These have received minimal investigation.

Guidelines for Use

• The Appropriate Wavelength: Most studies utilize wavelengths of 810–1064 nm, which are near-infrared, for optimal brain penetration. Visible red light (630–670 nm) is less frequently employed for brain applications due to its lower penetration capacity.

  
  

• Power Density: Published protocols indicate a wide range of densities, commonly between 20–250 mW/cm² at the scalp. Lower power densities (20–25 mW/cm²) are typical in certain cognitive enhancement studies, while higher values up to 250 mW/cm² are also used in cognitive, neurological, and psychiatric protocols. The optimal dosing remains uncertain and likely depends on wavelength, pulse structure, treatment duration, target, and clinical indication.

  
  

• The Dose is Important: For cognitive applications, including mild cognitive impairment, dementia, and traumatic brain injury, research generally employs energy levels ranging from 1–10 J/cm², although protocols vary widely. Higher-dose approaches have also been explored, particularly in relation to cerebral blood flow, metabolism, and neuroprotection. However, higher doses do not necessarily yield stronger clinical benefits, and considerations of safety, individual tolerability, and anatomy are crucial.

  
  

• Frequency is Crucial: Protocols differ significantly, making it essential to adhere to the guidelines provided by a qualified healthcare professional or the specific device in use. In published tPBM studies, treatment frequency typically ranges from about one to six sessions per week. For at-home LED panels or LED helmet devices (such as the Vielight), three sessions per week is common in many protocols, though some studies implement more frequent schedules.

  
  

  • Laser-based devices can deliver higher power densities and often necessitate less frequent sessions, such as one to three treatments weekly. However, protocols vary widely and depend on the dose, target, and indication rather than solely the light source.

  
  

• Type of Device: Both lasers and LEDs appear capable of inducing biological and clinical effects. Some analyses suggest that device characteristics, including the light source, may influence outcomes, but the current data does not support a clear conclusion that one is consistently superior to the other.

  
  

  • The most extensively studied devices direct infrared light at the head. Intranasal devices have also been examined, typically as an adjunct to transcranial treatment; however, data regarding this method remain preliminary, and further research is warranted.

  
  

• Individual Considerations: Hair can impede light delivery, as it absorbs and scatters a portion of the incoming light before it reaches the scalp. This is one reason many studies focus on the forehead, where hair is typically minimal or absent, although helmet-style devices treating hair-covered scalps have also yielded positive outcomes. Parting the hair may assist, and generally, denser or thicker hair may diminish the amount of light reaching the scalp and brain.

  
  

  • Similarly, skin pigmentation may also affect light penetration. Darker skin tones can enhance absorption of certain red and near-infrared wavelengths, which could limit the dose reaching deeper tissues. However, the extent of this effect in clinical practice is still under investigation.

  
  

• The Biphasic Dose Response: The biphasic dose response indicates that this often works optimally within a specific dosing range: insufficient amounts may have minimal effect, an intermediate dose may yield the greatest benefit, and excessive doses may diminish that benefit (creating an inverted U-shaped curve). As this response can vary based on wavelength, power, treatment duration, target, and condition, it is vital to collaborate with a provider who can assist in determining the appropriate dose for your specific condition.

  
  

• Safety: tPBM is generally well-tolerated, with few adverse effects reported. It is advisable to always use eye protection, even with LED devices, and it is absolutely essential with laser devices. However, long-term safety and efficacy data regarding this therapy are limited, and research is ongoing.